Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
Clinical trial NCT05971199 · UNKNOWN
Trial details
- NCT number
- NCT05971199
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-23
- Primary completion
- 2024-12-23
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.